Skip to content

Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis

Mohammad Saad Javed, Rayane El-Khoury, Amr Taha, Shuja Mohd Reagu

BMC Psychiatry February 9, 2026 DOI: 10.1186/s12888-025-07382-2 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review and meta-analysis Peer reviewed
Sample size 7,515
Population Patients diagnosed with cannabis-induced psychosis
Topics Cannabis
Citations 2
Key findings Among patients with cannabis-induced psychosis, pooled prevalence estimates were 20% for later schizophrenia spectrum diagnosis, 5% for bipolar disorder, and 63% for unspecified (both). Patients were 76% less likely to develop bipolar disorder than a schizophrenia spectrum disorder, and later unspecified diagnosis showed an approximately 3-fold higher risk (ARR 2.52) than schizophrenia spectrum disorder alone.

Abstract

Background: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis.

Methods: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence.

Results: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone.

Conclusions: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.

Comparable studies

Other systematic reviews and meta-analyses on cannabis, most cited first.

Study Year Design Participants
Effects of cannabis use on outcomes of psychotic disorders: systematic review People with psychotic disorders, as examined in 13 longitudinal studies 2008 Systematic review
The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... 2010 Meta-analysis and cross-sectional observational study n = 700
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review 2020 Systematic review
Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies 2009 Systematic review
Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia 2016 Systematic review

Citations in the library

Explore topics